NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE265980 Query DataSets for GSE265980
Status Public on May 03, 2024
Title A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, untargeted]
Organism Homo sapiens
Experiment type Non-coding RNA profiling by high throughput sequencing
Summary Circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employ a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals with T1DM from the INNODIA consortium. Our findings reveal that a set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two subgroups of individuals. To validate our results, we conduct additional analyses on a second cohort of T1DM individuals, confirming the identification of these subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibit increased expression of a set of 14q32 miRNAs, show better glycaemic control and display a different blood immunomics profile. Our findings suggest that this set of circulating microRNAs can identify two different T1DM subgroups with distinct blood immunomics at baseline and clinical outcomes during follow-up.
 
Overall design The study design involved the analysis of two cohorts of Type 1 Diabetes (T1DM) subjects: an initial screening cohort, the INNODIA first cohort, consisting of n=115 T1DM individuals, and a validation cohort, the INNODIA second cohort, consisting of n=147 T1DM individuals. All subjects were followed-up with programmed visits at 3 (visit 2), 6 (visit 3) and 12 months (visit 4) after clinical diagnosis of T1DM. In both cohorts, blood samples were collected at baseline (visit 1) and processed within 2 hours from blood draw. The collected blood samples underwent centrifugation to separate plasma from contaminant cells and platelets. The plasma samples were then aliquoted (200 μL) and stored at -80°C in a centralized biobank. For the INNODIA first cohort, the plasma samples were subjected to miRNA profiling using two different sequencing platforms: HTG-miRNA Edge Seq and Small RNA-seq. The profiling was followed by validation using droplet digital PCR. For the validation cohort, the plasma samples were analyzed using small RNA-seq, and subsequently validated using droplet digital PCR.
 
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Apr 26, 2024
Last update date May 03, 2024
Contact name Francesco Dotta
E-mail(s) francesco.dotta@unisi.it
Organization name University of Siena
Department Department of Medicine, surgery and neuroscience
Street address Viale Bracci 16
City Siena
State/province Si
ZIP/Postal code 53100
Country Italy
 
Platforms (1)
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Samples (121)
GSM8238723 Plasma,T1D,S1
GSM8238724 Plasma,T1D,S2
GSM8238725 Plasma,T1D,S3
Relations
BioProject PRJNA1105085

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE265980_First_cohort_Untargeted.csv.gz 315.6 Kb (ftp)(http) CSV
SRA Run SelectorHelp
Raw data are available in SRA
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap